Navigation Links
Immucor Appoints New Board Director
Date:12/16/2009

NORCROSS, Ga., Dec. 16 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that Paul D. Mintz, M.D. has been appointed to its board as a new independent director, effective January 1, 2010.

Dr. Mintz has been involved in blood banking and transfusion medicine for more than 30 years. He is a tenured Professor of Pathology and Medicine at the University of Virginia School of Medicine. He also serves as director of the University of Virginia Health System's Clinical Laboratories and Transfusion Medicine Services as well as Chief of the Department of Pathology's Division of Clinical Pathology. Dr. Mintz is also a co-medical director of Virginia Blood Services.

Dr. Mintz has served on numerous national and regional boards and committees throughout his career for such agencies and organizations as the Centers for Medicare and Medicaid Services, the National Blood Foundation and the AABB (formerly the American Association of Blood Banks). He is a past president of AABB and served for several years on its FDA Advisory Committee, including as past chair.

"Paul is the chair of Immucor's Scientific Advisory Board, which provides scientific expertise and strategic counsel on a variety of scientific and technical issues," stated Joseph Rosen, Immucor's Chairman of the Board. "Paul's extensive experience in transfusion medicine and familiarity with Immucor make him a valuable addition to Immucor's Board of Directors."

Dr. Mintz was a recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute. He has authored or co-authored more than 100 journal articles in blood banking and transfusion medicine.

Dr. Mintz will stand for regular election to a one-year term at the Company's next annual shareholders' meeting. The addition of Dr. Mintz expands the Company's board size to eight directors.

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.

SOURCE Immucor, Inc.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shareholder Class Action Filed Against Immucor, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Immucor to Announce Fiscal First Quarter Financial Results on Thursday, October 1, 2009
3. Immucor to Present at Upcoming Investor Conferences
4. Immucor Announces Fiscal Fourth Quarter Results
5. Immucor Appoints Chief Operating Officer
6. Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
7. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
8. Immucor Announces Fiscal Year 2010 Guidance
9. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
10. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
11. Immucor Receives Subpoena From Department of Justice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® ... area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony ... Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ...
(Date:12/4/2016)... Washington DC (PRWEB) , ... December 04, 2016 , ... ... Environmental, one of the most certified and experienced Indoor Air Quality Companies in VA, ... Assessment and Remediation Regulations. , The new mold law in the district ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: